An interventional study of 100% watermelon juice and Placebo beverage in Arterial Stiffness and Inflammation, sponsored by University of Alabama, Tuscaloosa. Completed. Open to female participants aged 55 Years to 69 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-05-17.
Sponsored by University of Alabama, Tuscaloosa · Not applicable, Interventional, and Prevention
Watermelon is the only food with a unique combination of amino acids and antioxidants that may reduce artery stiffness. However, only 27% of older adults meet the daily recommendation for fruit intake. Because it tastes good and is convenient and easy to consume, watermelon juice is an innovative and impactful intervention to help elders easily meet recommendations for fruit servings. If effective, this intervention would be a simple, inexpensive way to combat cardiovascular diseases (CVD). Results will advance science by providing a better understanding whether four-week consumption of 100% watermelon juice may impact measures of vascular health and inflammation in postmenopausal women.
Purpose and Objectives:
Vascular endothelial dysfunction is an early independent predictor of cardiovascular diseases (CVD), the leading cause of death for women ages 60 and older in the United States1. It is well-known that age-related decreases in vascular endothelial function are partially due to increases in oxidative stress and inflammation.In attempts to combat CVD, previous intervention studies have investigated provision of isolated bioactive food compounds (BFC) in supplemental form. For example, purified lycopene has been shown to decrease oxidative stress, and our previous work supports the supplemental use of glutamine and arginine in improving vascular endothelial function of older adults. Arginine is a precursor for the vasodilatory molecule nitric oxide (NO), and both glutamine and arginine have been shown to attenuate inflammation. Thus, if supplemented together, these compounds would be expected to exert synergist mechanistic effects that improve vascular function.
Watermelon is one of the richest sources of lycopene, and it is among the greatest plant sources of arginine and glutamine. Watermelon also provides high amounts of citrulline (a precursor of arginine) along with the antioxidant ascorbic acid, which enhances the antioxidant and anti-inflammatory effects of carotenoids such as lycopene in biological samples. To date, clinical studies evaluating the potential synergy of these compounds provided by the whole food are lacking on mechanistic and clinical outcomes of CVD. The effects of watermelon supplementation on robust measures of vascular function, inflammation, and oxidative stress in women ages 60 and older are unknown. This study will evaluate the possible impact of multiple bioactive compounds in the natural food matrix of watermelon in order to fully characterize their potential synergy and their influence on CVD risk. Specifically, our proposed study seeks to evaluate the influence of bioactive compounds in 100% watermelon juice, a convenient serving alternative to fresh fruit, using a randomized, double-blind placebo-controlled trial with a crossover design.
Specific Aims:
Mechanistic: To determine whether community-dwelling, non-obese women ages 55-69 consuming two 12-ounce servings of 100% watermelon juice per day versus placebo for four weeks will demonstrate:
Clinical: To determine whether community-dwelling, women ages 55-69 consuming two 12-ounce servings of 100% watermelon juice per day versus placebo for four weeks will exhibit:
3,439 studies on the registry are indexed under Inflammation; 629 are open to participants now.
This study's enrollment of 21 is below the median of 50 across 2,437 interventional studies indexed under Inflammation.
Browse Inflammation studies →University of Alabama, Tuscaloosa is the lead sponsor of 39 studies on the registry; 15 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Consumption of two 12-ounce doses of pasteurized 100% watermelon juice for a four-week period
Dietary Supplement: 100% watermelon juice
Consumption of a placebo beverage with comparable sugar content, pH, taste, texture, and color for a four-week period
Other: Placebo beverage
Participants drank two 12-ounce servings of 100% watermelon juice per day for a four-week period.
Participants drank two 12-ounce servings of a placebo beverage per day for a four-week period.
Change From Baseline in Serum Levels of Lycopene at 4 Weeks
Lycopene determined by ultra high performance liquid chromatography with photodiode array detector (UPLC-PDA).
Time frame: Baseline and 4 Weeks
Change in Vascular Endothelial Function at 4 Weeks
Determined by brachial artery flow-mediated dilation (FMD). FMD uses ultrasound technology to quantify changes in brachial artery diameter in response to hyperemia. A blood pressure cuff was placed distal to the brachial artery of the right arm with the participant supine and rested. Pre-inflation diameter was recorded for one minute, and the cuff was inflated to 50 mmHg above resting SBP for five minutes. Then, images were recorded for 120 seconds after cuff deflation. Peak diameter was determined as an average of the five highest measurements over five seconds post-deflation. FMD was expressed as the percentage increase in peak diameter.
Time frame: Baseline and 4 weeks
Change in Arterial Stiffness at 4 Weeks
Determined by pulse wave velocity (PWV). A cuff-based system was used to measure brachial oscillometric pressure waveforms and generate central pressure curves by propriety algorithms. PWV was quantified as the rate at which a pulse wave moves down a vessel.
Time frame: Baseline and 4 weeks
| Milestone | 100% Watermelon Juice First, Then Placebo Beverage | Placebo Beverage First, Then 100% Watermelon Juice |
|---|---|---|
| Started | 9 | 12 |
| Completed | 8 | 11 |
| Not completed | 1 | 1 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: Began a medication that precluded participation | 0 | 1 |
| Milestone | 100% Watermelon Juice First, Then Placebo Beverage | Placebo Beverage First, Then 100% Watermelon Juice |
|---|---|---|
| Started | 8 | 11 |
| Completed | 8 | 11 |
| Not completed | 0 | 0 |
| Milestone | 100% Watermelon Juice First, Then Placebo Beverage | Placebo Beverage First, Then 100% Watermelon Juice |
|---|---|---|
| Started | 8 | 11 |
| Completed | 8 | 9 |
| Not completed | 0 | 2 |
| Withdrew: Withdrawal by subject | 0 | 2 |
Lycopene determined by ultra high performance liquid chromatography with photodiode array detector (UPLC-PDA).
| uM | Consumption of 100% Watermelon Juice | Consumption of a Placebo Beverage |
|---|---|---|
| Change From Baseline in Serum Levels of Lycopene at 4 Weeks | 7.30 ± 7.55 | 3.09 ± 4.92 |
Determined by brachial artery flow-mediated dilation (FMD). FMD uses ultrasound technology to quantify changes in brachial artery diameter in response to hyperemia. A blood pressure cuff was placed distal to the brachial artery of the right arm with the participant supine and rested. Pre-inflation diameter was recorded for one minute, and the cuff was inflated to 50 mmHg above resting SBP for five minutes. Then, images were recorded for 120 seconds after cuff deflation. Peak diameter was determined as an average of the five highest measurements over five seconds post-deflation. FMD was expressed as the percentage increase in peak diameter.
| percentage of change in diameter | Consumption of 100% Watermelon Juice | Consumption of a Placebo Beverage |
|---|---|---|
| Change in Vascular Endothelial Function at 4 Weeks | 2.85 ± 7.81 | 2.17 ± 9.25 |
Determined by pulse wave velocity (PWV). A cuff-based system was used to measure brachial oscillometric pressure waveforms and generate central pressure curves by propriety algorithms. PWV was quantified as the rate at which a pulse wave moves down a vessel.
| meters/second | Consumption of 100% Watermelon Juice | Consumption of a Placebo Beverage |
|---|---|---|
| Change in Arterial Stiffness at 4 Weeks | -0.029 ± 0.269 | -0.188 ± 0.486 |
Collected over Four weeks for each intervention. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Consumption of 100% Watermelon Juice | 0/17 (0%) | 0/17 (0%) | 0/17 (0%) |
| Consumption of a Placebo Beverage | 0/17 (0%) | 0/17 (0%) | 0/17 (0%) |
One participant was randomized, but she began taking a hypertension medication that precluded her participation prior to baseline testing. Three other participants withdrew from the study before completion, but they completed baseline testing.
| Age, Continuous(years) | 100% Watermelon Juice First, Then Placebo Beverage | Placebo Beverage First, Then 100% Watermelon Juice | Total |
|---|---|---|---|
| Mean | 61.78 ± 4.99 | 58.91 ± 2.91 | 60.20 ± 4.14 |
| Sex: Female, Male(Participants) | 100% Watermelon Juice First, Then Placebo Beverage | Placebo Beverage First, Then 100% Watermelon Juice | Total |
|---|---|---|---|
| Female | 9 | 11 | 20 |
| Male | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | 100% Watermelon Juice First, Then Placebo Beverage | Placebo Beverage First, Then 100% Watermelon Juice | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 9 | 11 | 20 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | 100% Watermelon Juice First, Then Placebo Beverage | Placebo Beverage First, Then 100% Watermelon Juice | Total |
|---|---|---|---|
| United States | 9 | 11 | 20 |
| Weight(kg) | 100% Watermelon Juice First, Then Placebo Beverage | Placebo Beverage First, Then 100% Watermelon Juice | Total |
|---|---|---|---|
| Mean | 59.69 ± 10.07 | 69.96 ± 5.75 | 65.34 ± 9.36 |
| Body mass index (BMI)(kg/m^2) | 100% Watermelon Juice First, Then Placebo Beverage | Placebo Beverage First, Then 100% Watermelon Juice | Total |
|---|---|---|---|
| Mean | 22.61 ± 3.21 | 27.12 ± 2.51 | 25.08 ± 3.60 |
| Serum lycopene(uM) | 100% Watermelon Juice First, Then Placebo Beverage | Placebo Beverage First, Then 100% Watermelon Juice | Total |
|---|---|---|---|
| Mean | 1.55 ± 0.70 | 1.26 ± 0.87 | 1.37 ± 0.80 |
| Serum arginine(uM) | 100% Watermelon Juice First, Then Placebo Beverage | Placebo Beverage First, Then 100% Watermelon Juice | Total |
|---|---|---|---|
| Mean | 65.51 ± 24.54 | 54.64 ± 16.10 | 58.87 ± 19.87 |
6 further baseline measures are reported on the registry.
No study locations are listed for this record.
Documents are hosted by the registry — open the source record to download them.
Plan to share: No
This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Alabama, Tuscaloosa